Eli Lilly & Co (LLY) experienced a significant surge in market capitalization last week, recording an impressive increase of $51.0 billion. This surge in market cap propelled the company's stock price to $431.19. The 14.6% jump in market cap marked Eli Lilly & Co as the leader in terms of market cap growth among 57 stocks analyzed in the Pharmaceuticals: Major Industry by A.I.dvisor for the week ending May 3, 2023.
AI analysis revealed that out of the 57 stocks in the Pharmaceuticals: Major Industry, 34 of them, accounting for 58.82%, were in an uptrend. This indicates positive performance and upward momentum in the industry. On the other hand, 23 stocks, representing 41.18% of the total, were observed to be in a downtrend, suggesting a decline in their market performance.
Eli Lilly & Co's impressive market cap increase not only showcases its strong performance but also reflects investors' confidence in the company's future prospects. This surge in market cap indicates a favorable market sentiment towards Eli Lilly & Co and its position within the pharmaceutical industry.
Investors and stakeholders will closely monitor Eli Lilly & Co's performance in the coming weeks to gauge the sustainability of this growth. Furthermore, the overall trend in the Pharmaceuticals: Major Industry will also be a point of interest as market dynamics continue to evolve.
LLY's Aroon Indicator triggered a bullish signal on September 22, 2023. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 351 similar instances where the Aroon Indicator showed a similar pattern. In of the 351 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 360 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for LLY moved out of overbought territory on September 15, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 21, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on September 15, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LLY broke above its upper Bollinger Band on September 07, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (47.170) is very high in comparison to the industry average of (6.139). LLY has a moderately high P/E Ratio (76.923) as compared to the industry average of (31.865). Projected Growth (PEG Ratio) (1.451) is also within normal values, averaging (3.317). LLY has a moderately low Dividend Yield (0.008) as compared to the industry average of (0.028). LLY's P/S Ratio (16.863) is very high in comparison to the industry average of (3.735).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with BIIB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then BIIB could also see price increases.